Legend Biotech Corporation is an innovative clinical-stage biopharmaceutical company focused on developing advanced CAR-T cell therapies primarily for oncology applications. With a strong commitment to addressing significant unmet medical needs, the company boasts a promising pipeline strengthened by rigorous clinical research and strategic partnerships. As it advances through critical clinical trials, Legend Biotech presents a compelling investment opportunity for institutional investors looking to capitalize on breakthroughs in immuno-oncology and the broader biopharmaceutical landscape. Show more

Location: 2101 COTTONTAIL LANE, SOMERSET, NJ, UNITED STATES, 08873, Somerset, NJ, 08873, USA | Website: https://www.legendbiotech.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

3.084B

52 Wk Range

$16.24 - $45.30

Previous Close

$16.70

Open

$16.88

Volume

2,546,484

Day Range

$16.88 - $17.27

Enterprise Value

2.491B

Cash

278.9M

Avg Qtr Burn

N/A

Insider Ownership

1.30%

Institutional Own.

47.44%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details Blood cancer, Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CARVYKTI (cilta-cel) Details Blood cancer, Cancer, Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (DVRd) Details Multiple myeloma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB2102 Details Cancer, Small cell lung cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LUCAR-G39D (Allogeneic CAR-T) Details Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB1901 Details Cancer, T-cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.